Newsletter Signup
Where current and emerging technology trends meet.
TecTrendsInformation Sources, Inc.
  | About TecTrends | Email Signup | Contact Us
 Live Search:
Live Search | Articles | Companies | TecTerms | Products
  Loading TecTrends Live Search - please wait... 
View Noteworthy Articles      PRNewswire
 
Company

FibroGen Inc Products   
225 Gateway Blvd
South San Francisco,  CA  94080
United States
Telephone: (650) 866-7200
Fax: (650) 866-7201
URL: http://www.fibrogen.com
Email: info@fibrogen.com

FibroGen Incorporated, launched in 1995 and based in South San Francisco, California, is a biotechnology firm that develops treatments for fibrotic disease, anemia, tissue damage conditions, and cancer. The company's products are built on prolyl hydroxylase (PH) inhibition and hypoxia-inducible factor (HIF) stabilization research. The firm's FG-3019 product candidate, in clinical development, is a human antibody that blocks connective tissue growth factor (CTGF) activity. FG-2216 is an erythropoietic small molecule drug that treats anemia. FG-45-39 is a cytoprotective small molecule drug that treats delayed graft function. The FG-5030 and FG-5017 recombinant human collagen product candidates are injectable dermal fillers. FibroGen maintains additional operations in Helsinki, Finland.

Org. Type: Corporation Equity Type: Private
Company Status: Active

Products:
FibroGen Inc--Company News

TecTerms:
 


Home About TecTrends About Us Contact Us Privacy Statement Terms and Conditions

TecTrends | P.O. Box 8120 | Berkeley CA 94707 | (510) 525-6220 | Email: tectrends@tectrends.com
© 2006 INFORMATION SOURCES INC | All rights reserved.